Etoricoxib 120 mg tablets,Arcoxia 120 mg tablets
Sponsors
Bio-innova and Synchron.Co.,Ltd, Bio-innova Co., Ltd.
Conditions
Healthy subjects
Bioequivalence
EtoricoxibHealthy subjects
Bioequivalence Etoricoxib 120 mg tablets
Phase 1
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Etoricoxib 120 mg tablets relative to Arcoxia 120 mg tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20210924005
Start: 2021-12-01Target: 28Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Etoricoxib 120 mg tablets relative to Arcoxia 120 mg tablets in healthy Thai volunteers under fasting condition
TCTR20221003005
Start: 2023-02-23Target: 28Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Etoricoxib 120 mg tablets relative to Arcoxia 120 mg tablets in healthy Thai volunteers under fasting condition
TCTR20230520001
Start: 2023-08-15Target: 28Updated: 2026-08-03